Sun Pharma Advanced Research Company Limited

rs,

Kurla Complex, Bandra (East), Mumbai – 400 051. BSE Limited, Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001. Ref: Scrip Code: NSE: SPARC; BSE: 532872 Dear Sir/Madam, Sub:

rs. 2

und by the foregoing limitations. All brand names and trademarks are the property of respective owners. 2 SPARC © 2022 Agenda 01 02 Overview Anil Raghavan 03 Biologics Nitin Damle 04 05 Financial Up

50%

igational New Drug SPARC © 2022 Attractive portfolio built using a cost-efficient structure Over 50% funded through non-dilutive revenue generated 2012 2016 2017 2021 Promoters’ share Others 2

rs 26

r 50% funded through non-dilutive revenue generated 2012 2016 2017 2021 Promoters’ share Others 26% 25% 7% 46% 74% 75% 93% 54% Rights issue 1 INR 198 cr / USD 41 mn Rights issue 2 INR 250

25%

ded through non-dilutive revenue generated 2012 2016 2017 2021 Promoters’ share Others 26% 25% 7% 46% 74% 75% 93% 54% Rights issue 1 INR 198 cr / USD 41 mn Rights issue 2 INR 250 cr /

7%

hrough non-dilutive revenue generated 2012 2016 2017 2021 Promoters’ share Others 26% 25% 7% 46% 74% 75% 93% 54% Rights issue 1 INR 198 cr / USD 41 mn Rights issue 2 INR 250 cr / USD

46%

gh non-dilutive revenue generated 2012 2016 2017 2021 Promoters’ share Others 26% 25% 7% 46% 74% 75% 93% 54% Rights issue 1 INR 198 cr / USD 41 mn Rights issue 2 INR 250 cr / USD 38 mn

74%

n-dilutive revenue generated 2012 2016 2017 2021 Promoters’ share Others 26% 25% 7% 46% 74% 75% 93% 54% Rights issue 1 INR 198 cr / USD 41 mn Rights issue 2 INR 250 cr / USD 38 mn Pre

75%

utive revenue generated 2012 2016 2017 2021 Promoters’ share Others 26% 25% 7% 46% 74% 75% 93% 54% Rights issue 1 INR 198 cr / USD 41 mn Rights issue 2 INR 250 cr / USD 38 mn Preferen

93%

revenue generated 2012 2016 2017 2021 Promoters’ share Others 26% 25% 7% 46% 74% 75% 93% 54% Rights issue 1 INR 198 cr / USD 41 mn Rights issue 2 INR 250 cr / USD 38 mn Preferential

54%

enue generated 2012 2016 2017 2021 Promoters’ share Others 26% 25% 7% 46% 74% 75% 93% 54% Rights issue 1 INR 198 cr / USD 41 mn Rights issue 2 INR 250 cr / USD 38 mn Preferential issue

INR 198

2016 2017 2021 Promoters’ share Others 26% 25% 7% 46% 74% 75% 93% 54% Rights issue 1 INR 198 cr / USD 41 mn Rights issue 2 INR 250 cr / USD 38 mn Preferential issue of convertible warrants

Patients on study after

1

Patients on study after

1 year: 71.7% 2 years: 52.8% 3 years: 37.7% Median duration on study = 23.9 months (range: 0.1 - 65.17 months) Discontinued study drug On treatment 0 10 20 30 40 50 60 70 Duration in months 17 Data cutoff: 1st September 2022 SPARC © 2022 Next steps Additional data to be presented at upcoming clinical conferences: the 2022 ESH John Goldman Conference and the 2022 ASH Annual Meeting Pivotal study readout in FY24 18 SPARC © 2022 Vodobatinib for Neurodegenerative diseases (SCC-138) A potential first- in-class disease modifying therapy targeting c-Abl c-Abl: a critical component of neurodegeneration Substantiated by multiple research groups Ubiquitous expression in nucleated cells • Expressed in all parts of the CNS (brain and spinal column, and peripheral neuronal tissue) Pivotal role in promoting neurodegeneration • Under oxidative stress, c-Abl is activated and phosphorylates a number of key substrates that bring about programmed death of oxidatively-stressed neurons CNS = Central Nervou